Tianyu Co., Ltd. (300702.SZ) issued an announcement. Zhejiang Nuode Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company (abbreviated below...
Zhitong Finance App News, Tianyu Co., Ltd. (300702.SZ) issued an announcement. Zhejiang Nuode Pharmaceutical Co., Ltd. (hereinafter referred to as “Nord Pharmaceutical”), a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for metformin viglitin tablets (III) and compound polyethylene glycol electrolyte dispersion (III) approved and issued by the State Drug Administration.
Metformin vilagliptin tablets (III): Suitable for adult type 2 diabetics: This product is used in combination with diet and exercise therapy. It is used for metformin monotherapy to reach the maximum tolerable dose, blood sugar is still poorly controlled, or is being treated in combination with vilglitine and metformin. When a stable dose of insulin combined with metformin is still not well controlled, this product can be used in combination with insulin to improve blood sugar control in combination with diet and exercise therapy. Compound polyethylene glycol electrolyte powder (III): used to prepare adults for colon cleansing before endoscopic or radiological examinations or colon surgery.
The company's products, metformin vigliptin tablets (III) and compound polyethylene glycol electrolyte dispersion (III), can be produced and sold domestically after receiving approval from the State Drug Administration, further enriching the company's formulation variety, which is expected to increase the company's formulation business revenue, help enhance the market competitiveness of the company's products, and have a positive impact on the company's business performance.